Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for ...

Good news for people on GLP-1 therapy who hate needles: Trial data out this week shows that an experimental pill developed by ...

Eli Lilly's oral pill, orforglipron, helped maintain weight loss in patients switching from injectable versions of GLP-1 ...

Eli Lilly seeks FDA approval for orforglipron, a once-daily pill shown in trials to help maintain weight loss after stopping ...

The company said some patients had dropped out of the trial because they felt they were losing too much weight.

Orforglipron helped keep weight down when used after initial therapy with an injectable, a new treatment strategy that could ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...

Although the injectable forms of the popular GLP-1 drugs are more effective, the pills under development are both easier to ...

Retatrutide, the next generation of GLP-1 drug from Eli Lilly, helped participants lose an average of 71.2 pounds and reduce ...

Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in ...